Word of mouth was that our members wanted to hear more about IPC and oral health! APIC's partnership with ADS (previously OSAP) is back! Join us for a series focusing on infection prevention and control in the Dental setting.

This series will provide tools for how IPs can become critical coaches in the deployment of these technologies within their organizations as the technology continues to emerge.

This series provides an opportunity for participants to hear from IPs and various department leaders about best practices and results which can be accomplished when leveraging strong inter-departmental relationships. This series focuses on construction and renovation.

Join us for a panel discussion and town hall on what’s happening in Washington. What is the possible impact on the field of infection prevention and control.  How can IPs get involved?

Understanding HLD & the risks of Endoscopy

Join CBIC for an informational and interactive session to learn more about the new Advanced Leadership Certification in Infection Prevention and Control (AL-CIP).

This webinar is an opportunity to hear directly from the presidents on what SHEA and APIC are doing together and what is planned for 2025.

This series provides an opportunity for participants to hear from IPs and various department leaders about best practices and results which can be accomplished when leveraging strong inter-departmental relationships.

High-consequence infectious diseases (HCIDs) or special pathogens are novel and reemerging infectious diseases or pathogens that are highly transmissible from person to person (or have an unknown mode of transmission) and have the potential for epidemic or pandemic with high morbidity and mortality. Examples of HCIDs or special pathogens include Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), COVID-19, measles, mpox, smallpox, novel or new mutation of influenza, and Ebola or other viral hemorrhagic fever diseases.

This webinar will provide the latest study results from three recently published meta-analyses on the effectiveness of antiseptics as compared to mupirocin. For IPs, being able to demonstrate the return on investment is an equally important piece to the puzzle for gaining adopted in their facility. Examples of value propositions IPs have used to successfully garner support for larger programs will be shared.